You are here

Article Text

Article menu
Download PDFPDF
Commentary
New role for azathioprine in case of switching anti-TNFs in IBD

https://doi.org/10.1136/gutjnl-2020-320677

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors KP: drafting and final approval of the manuscript; ASC: critical revision and final approval of the manuscript. PMI: critical revision and final approval of the manuscript.

    • Funding KP: Ruth L. Kirschstein NRSA Institutional Research Training Grant (5T32DK007760-18).

    • Competing interests KP: received a lecture fee from Mitsubishi Tanabe Pharma; ASC: received consultancy fees from AbbVie, Janssen, Takeda, Miraca, Ferring, AMAG and Pfizer; PMI has received honoraria for acting in an advisory capacity for or talking on behalf of AbbVie, Arena, Celgene, Falk Pharma, Ferring, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Prometheus, Roche, Takeda, Tillotts, Topivert, Sapphire Medical, Sandoz, Shire, VH2, Vifor Pharma, Warner Chilcott, and has received research support from MSD, Takeda and Pfizer.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles